US monkeypox testings market report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
Description
US Monkeypox Testings Market Overview
The US Monkeypox Testings Market is valued at USD 540 million, based on a five-year historical analysis. This growth is primarily driven by the increasing incidence of monkeypox cases, heightened public health awareness, expanded federal funding, and rapid advancements in molecular diagnostic technologies such as PCR and point-of-care testing. The market has seen a surge in demand for effective testing solutions, particularly in response to out
eaks and the need for rapid identification of cases.
Key players in this market include major cities such as New York, Los Angeles, and Chicago, which dominate due to their large populations, advanced healthcare infrastructure, and significant public health initiatives. These urban centers have been at the forefront of monkeypox testing efforts, leveraging their resources to implement widespread testing and surveillance programs.
In 2023, the US government implemented the Monkeypox Response Plan, which includes funding of USD 100 million to enhance testing capabilities and improve public health response strategies. This initiative aims to ensure timely access to testing and increase the overall preparedness of healthcare systems to manage monkeypox out
eaks effectively. The plan operates under the authority of the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (HHS), as outlined in the "Monkeypox Response Plan 2023" issued by HHS. Key operational measures include scaling laboratory capacity, expanding PCR and molecular testing, and establishing reimbursement mechanisms for diagnostic services.
US Monkeypox Testings Market Segmentation
By Type:
The market is segmented into various testing types, including PCR Testing, Serological Testing, Rapid Antigen Testing, Multiplex Assays, and Others. PCR Testing is the most widely used method due to its high sensitivity and specificity, making it the preferred choice for accurate diagnosis. The demand for Serological Testing is also growing, particularly for epidemiological studies and understanding population immunity. Rapid Antigen Testing and Multiplex Assays are gaining traction as point-of-care solutions, driven by the need for faster turnaround and
oader pathogen detection.
By End-User:
The end-user segmentation includes Hospitals, Diagnostic Laboratories, Public Health Organizations, Urgent Care Centers, and Others. Hospitals are the leading end-users, as they require rapid and accurate testing for patient management and out
eak control. Diagnostic Laboratories also play a crucial role in providing specialized testing services, while Public Health Organizations focus on surveillance and epidemiological studies. Urgent Care Centers and other outpatient facilities are increasingly adopting rapid and point-of-care testing to improve accessibility and response times.
US Monkeypox Testings Market Competitive Landscape
The US Monkeypox Testings Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Cepheid, Bio-Rad Laboratories, Hologic, Inc., Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp), Siemens Healthineers, PerkinElmer, Inc., Becton, Dickinson and Company (BD), GenMark Diagnostics, QIAGEN, DiaSorin S.p.A., Aegis Sciences Corporation, Mayo Clinic Laboratories, Chembio Diagnostics, Inc., Sonora Quest Laboratories, Sonic Healthcare USA contribute to innovation, geographic expansion, and service delivery in this space.
Abbott Laboratories
1888
Abbott Park, Illinois
Roche Diagnostics
1896
Basel, Switzerland
Thermo Fisher Scientific
2006
Waltham, Massachusetts
Cepheid
1996
Sunnyvale, California
Bio-Rad Laboratories
1952
Hercules, California
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
US Monkeypox Testing Revenue
Revenue Growth Rate (YoY)
Market Penetration Rate (US Market Share %)
Number of US Testing Sites/Facilities
Testing Throughput (Tests Processed per Day)
US Monkeypox Testings Market Industry Analysis
Growth Drivers
Increased Awareness and Education on Monkeypox:
The rise in public awareness regarding monkeypox has significantly influenced testing demand. In future, the CDC reported a 40% increase in educational campaigns, leading to a 30% rise in testing inquiries. This heightened awareness is crucial as it encourages individuals to seek testing, thereby facilitating early detection and containment of the virus. The focus on education is expected to continue, further driving testing rates in future.
Government Initiatives for Disease Control:
In future, the U.S. government allocated $50 million for monkeypox control initiatives, including testing programs. These initiatives aim to enhance testing accessibility and efficiency, particularly in high-risk areas. The funding supports the establishment of mobile testing units and community outreach programs, which are projected to increase testing rates by 25% in underserved populations. Such proactive measures are essential for effective disease management.
Technological Advancements in Testing Methods:
The introduction of rapid testing technologies has revolutionized monkeypox diagnostics. In future, the FDA approved three new rapid testing kits, reducing testing time to under 30 minutes. This advancement is expected to increase testing capacity by 50% in future, as healthcare facilities adopt these efficient methods. Enhanced accuracy and speed in testing are critical for timely public health responses and containment efforts.
Market Challenges
Limited Availability of Testing Kits:
Despite advancements, the availability of monkeypox testing kits remains a significant challenge. In future, only 60% of healthcare facilities reported having adequate testing supplies. This shortage is exacerbated by supply chain disruptions and increased global demand. As a result, many facilities are unable to meet the testing needs of their communities, potentially delaying diagnosis and treatment, which could lead to further out
eaks.
Public Misinformation and Stigma:
Misinformation surrounding monkeypox has created stigma, deterring individuals from seeking testing. A future survey indicated that 35% of respondents felt embarrassed to get tested due to societal perceptions. This stigma can lead to underreporting of cases and hinder public health efforts. Addressing misinformation through targeted campaigns is essential to encourage testing and reduce the stigma associated with the disease.
US Monkeypox Testings Market Future Outlook
The future of the US monkeypox testing market appears promising, driven by ongoing government support and technological innovations. As awareness campaigns continue to educate the public, testing rates are expected to rise significantly. Additionally, the integration of telehealth services is likely to enhance accessibility, allowing individuals to receive guidance and testing from the comfort of their homes. These trends indicate a proactive approach to managing monkeypox, ultimately leading to improved public health outcomes.
Market Opportunities
Expansion of Testing Facilities:
There is a significant opportunity to expand testing facilities, particularly in rural and underserved areas. By increasing the number of testing sites, access to testing can improve, potentially increasing the number of tests conducted by 40% in these regions. This expansion is crucial for early detection and containment of monkeypox out
eaks.
Partnerships with Healthcare Providers:
Collaborating with healthcare providers can enhance testing outreach and efficiency. Strategic partnerships can facilitate the distribution of testing kits and educational resources, potentially increasing testing rates by 30%. Such collaborations are vital for creating a comprehensive response to monkeypox and ensuring that testing is accessible to all populations.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
The US Monkeypox Testings Market is valued at USD 540 million, based on a five-year historical analysis. This growth is primarily driven by the increasing incidence of monkeypox cases, heightened public health awareness, expanded federal funding, and rapid advancements in molecular diagnostic technologies such as PCR and point-of-care testing. The market has seen a surge in demand for effective testing solutions, particularly in response to out
eaks and the need for rapid identification of cases.
Key players in this market include major cities such as New York, Los Angeles, and Chicago, which dominate due to their large populations, advanced healthcare infrastructure, and significant public health initiatives. These urban centers have been at the forefront of monkeypox testing efforts, leveraging their resources to implement widespread testing and surveillance programs.
In 2023, the US government implemented the Monkeypox Response Plan, which includes funding of USD 100 million to enhance testing capabilities and improve public health response strategies. This initiative aims to ensure timely access to testing and increase the overall preparedness of healthcare systems to manage monkeypox out
eaks effectively. The plan operates under the authority of the Centers for Disease Control and Prevention (CDC) and the Department of Health and Human Services (HHS), as outlined in the "Monkeypox Response Plan 2023" issued by HHS. Key operational measures include scaling laboratory capacity, expanding PCR and molecular testing, and establishing reimbursement mechanisms for diagnostic services.
US Monkeypox Testings Market Segmentation
By Type:
The market is segmented into various testing types, including PCR Testing, Serological Testing, Rapid Antigen Testing, Multiplex Assays, and Others. PCR Testing is the most widely used method due to its high sensitivity and specificity, making it the preferred choice for accurate diagnosis. The demand for Serological Testing is also growing, particularly for epidemiological studies and understanding population immunity. Rapid Antigen Testing and Multiplex Assays are gaining traction as point-of-care solutions, driven by the need for faster turnaround and
oader pathogen detection.
By End-User:
The end-user segmentation includes Hospitals, Diagnostic Laboratories, Public Health Organizations, Urgent Care Centers, and Others. Hospitals are the leading end-users, as they require rapid and accurate testing for patient management and out
eak control. Diagnostic Laboratories also play a crucial role in providing specialized testing services, while Public Health Organizations focus on surveillance and epidemiological studies. Urgent Care Centers and other outpatient facilities are increasingly adopting rapid and point-of-care testing to improve accessibility and response times.
US Monkeypox Testings Market Competitive Landscape
The US Monkeypox Testings Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Cepheid, Bio-Rad Laboratories, Hologic, Inc., Quest Diagnostics, Laboratory Corporation of America Holdings (LabCorp), Siemens Healthineers, PerkinElmer, Inc., Becton, Dickinson and Company (BD), GenMark Diagnostics, QIAGEN, DiaSorin S.p.A., Aegis Sciences Corporation, Mayo Clinic Laboratories, Chembio Diagnostics, Inc., Sonora Quest Laboratories, Sonic Healthcare USA contribute to innovation, geographic expansion, and service delivery in this space.
Abbott Laboratories
1888
Abbott Park, Illinois
Roche Diagnostics
1896
Basel, Switzerland
Thermo Fisher Scientific
2006
Waltham, Massachusetts
Cepheid
1996
Sunnyvale, California
Bio-Rad Laboratories
1952
Hercules, California
Company
Establishment Year
Headquarters
Group Size (Large, Medium, or Small as per industry convention)
US Monkeypox Testing Revenue
Revenue Growth Rate (YoY)
Market Penetration Rate (US Market Share %)
Number of US Testing Sites/Facilities
Testing Throughput (Tests Processed per Day)
US Monkeypox Testings Market Industry Analysis
Growth Drivers
Increased Awareness and Education on Monkeypox:
The rise in public awareness regarding monkeypox has significantly influenced testing demand. In future, the CDC reported a 40% increase in educational campaigns, leading to a 30% rise in testing inquiries. This heightened awareness is crucial as it encourages individuals to seek testing, thereby facilitating early detection and containment of the virus. The focus on education is expected to continue, further driving testing rates in future.
Government Initiatives for Disease Control:
In future, the U.S. government allocated $50 million for monkeypox control initiatives, including testing programs. These initiatives aim to enhance testing accessibility and efficiency, particularly in high-risk areas. The funding supports the establishment of mobile testing units and community outreach programs, which are projected to increase testing rates by 25% in underserved populations. Such proactive measures are essential for effective disease management.
Technological Advancements in Testing Methods:
The introduction of rapid testing technologies has revolutionized monkeypox diagnostics. In future, the FDA approved three new rapid testing kits, reducing testing time to under 30 minutes. This advancement is expected to increase testing capacity by 50% in future, as healthcare facilities adopt these efficient methods. Enhanced accuracy and speed in testing are critical for timely public health responses and containment efforts.
Market Challenges
Limited Availability of Testing Kits:
Despite advancements, the availability of monkeypox testing kits remains a significant challenge. In future, only 60% of healthcare facilities reported having adequate testing supplies. This shortage is exacerbated by supply chain disruptions and increased global demand. As a result, many facilities are unable to meet the testing needs of their communities, potentially delaying diagnosis and treatment, which could lead to further out
eaks.
Public Misinformation and Stigma:
Misinformation surrounding monkeypox has created stigma, deterring individuals from seeking testing. A future survey indicated that 35% of respondents felt embarrassed to get tested due to societal perceptions. This stigma can lead to underreporting of cases and hinder public health efforts. Addressing misinformation through targeted campaigns is essential to encourage testing and reduce the stigma associated with the disease.
US Monkeypox Testings Market Future Outlook
The future of the US monkeypox testing market appears promising, driven by ongoing government support and technological innovations. As awareness campaigns continue to educate the public, testing rates are expected to rise significantly. Additionally, the integration of telehealth services is likely to enhance accessibility, allowing individuals to receive guidance and testing from the comfort of their homes. These trends indicate a proactive approach to managing monkeypox, ultimately leading to improved public health outcomes.
Market Opportunities
Expansion of Testing Facilities:
There is a significant opportunity to expand testing facilities, particularly in rural and underserved areas. By increasing the number of testing sites, access to testing can improve, potentially increasing the number of tests conducted by 40% in these regions. This expansion is crucial for early detection and containment of monkeypox out
eaks.
Partnerships with Healthcare Providers:
Collaborating with healthcare providers can enhance testing outreach and efficiency. Strategic partnerships can facilitate the distribution of testing kits and educational resources, potentially increasing testing rates by 30%. Such collaborations are vital for creating a comprehensive response to monkeypox and ensuring that testing is accessible to all populations.
Please Note: It will take 5-7 business days to complete the report upon order confirmation.
Table of Contents
83 Pages
- 1. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1 Increased Awareness and Education on Monkeypox
- 3.1.2 Government Initiatives for Disease Control
- 3.1.3 Technological Advancements in Testing Methods
- 3.1.4 Rising Incidence of Monkeypox Cases
- 3.2. Restraints
- 3.2.1 Limited Availability of Testing Kits
- 3.2.2 High Costs of Testing Procedures
- 3.2.3 Regulatory Hurdles in Test Approval
- 3.2.4 Public Misinformation and Stigma
- 3.3. Opportunities
- 3.3.1 Expansion of Testing Facilities
- 3.3.2 Partnerships with Healthcare Providers
- 3.3.3 Development of Rapid Testing Solutions
- 3.3.4 Increased Funding for Research and Development
- 3.4. Trends
- 3.4.1 Shift Towards Home Testing Solutions
- 3.4.2 Integration of AI in Diagnostic Processes
- 3.4.3 Focus on Preventive Healthcare
- 3.4.4 Rise in Telehealth Services for Testing
- 3.5. Government Regulation
- 3.5.1 FDA Approval Processes for Testing Kits
- 3.5.2 State-Level Health Regulations
- 3.5.3 Reporting Requirements for Testing Facilities
- 3.5.4 Guidelines for Monkeypox Testing Protocols
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Segmentation, 2024
- 4.1. By Type (in Value %)
- 4.1.1 PCR Testing
- 4.1.2 Serological Testing
- 4.1.3 Rapid Antigen Testing
- 4.1.4 Multiplex Assays
- 4.1.5 Others
- 4.2. By End-User (in Value %)
- 4.2.1 Hospitals
- 4.2.2 Diagnostic Laboratories
- 4.2.3 Public Health Organizations
- 4.2.4 Urgent Care Centers
- 4.2.5 Others
- 4.3. By Distribution Channel (in Value %)
- 4.3.1 Direct Sales
- 4.3.2 Online Sales
- 4.3.3 Distributors
- 4.3.4 Others
- 4.4. By Application (in Value %)
- 4.4.1 Clinical Testing
- 4.4.2 Research and Development
- 4.4.3 Surveillance Programs
- 4.4.4 Outbreak Response
- 4.4.5 Others
- 4.5. By Pricing Model (in Value %)
- 4.5.1 Premium Pricing
- 4.5.2 Competitive Pricing
- 4.5.3 Value-Based Pricing
- 4.5.4 Reimbursement-Based Pricing
- 4.5.5 Others
- 4.6. By Region (in Value %)
- 4.6.1 Northeast
- 4.6.2 Midwest
- 4.6.3 South
- 4.6.4 West
- 4.6.5 Central
- 4.6.6 Northwest
- 4.6.7 Southwest
- 5. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1 Abbott Laboratories
- 5.1.2 Roche Diagnostics
- 5.1.3 Thermo Fisher Scientific
- 5.1.4 Cepheid
- 5.1.5 Bio-Rad Laboratories
- 5.2. Cross Comparison Parameters
- 5.2.1 US Monkeypox Testing Revenue
- 5.2.2 Revenue Growth Rate (YoY)
- 5.2.3 Market Penetration Rate (US Market Share %)
- 5.2.4 Number of US Testing Sites/Facilities
- 5.2.5 Testing Accuracy Rate (Sensitivity/Specificity %)
- 6. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Regulatory Framework
- 6.1. Compliance Requirements and Audits
- 6.2. Certification Processes
- 6.3. Reporting Standards
- 7. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. US monkeypox testings Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Segmentation, 2030
- 8.1. By Type (in Value %)
- 8.2. By End-User (in Value %)
- 8.3. By Distribution Channel (in Value %)
- 8.4. By Application (in Value %)
- 8.5. By Pricing Model (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
